PriceTargets.com logo

I-Mab - IMAB Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.25
  • Forecasted Upside: 580.56%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$1.80 As of 04/26/2024 01:00 AM ET
▼ -0.01 (-0.55%)

This chart shows the closing price for IMAB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New I-Mab Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMAB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMAB

Analyst Price Target is $12.25
▲ +580.56% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for I-Mab in the last 3 months. The average price target is $12.25, with a high forecast of $25.00 and a low forecast of $6.00. The average price target represents a 580.56% upside from the last price of $1.80.

This chart shows the closing price for IMAB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in I-Mab. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/28/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/12/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$6.00Low
3/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$18.00 ➝ $8.00Low
3/18/2024Piper SandlerLower TargetOverweight ➝ Overweight$15.00 ➝ $10.00Low
3/15/2024Needham & Company LLCLower TargetBuy ➝ Buy$8.00 ➝ $6.00N/A
2/8/2024Needham & Company LLCLower TargetBuy ➝ Buy$23.00 ➝ $8.00Low
1/12/2024Cantor FitzgeraldReiterated RatingOverweightLow
12/18/2023Cantor FitzgeraldReiterated RatingOverweightLow
9/25/2023Needham & Company LLCLower TargetBuy ➝ Buy$24.00 ➝ $23.00Low
9/5/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$25.00Low
8/18/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$25.00Low
8/18/2023HC WainwrightLower TargetBuy ➝ Buy$25.00 ➝ $18.00Low
8/18/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$24.00Low
4/19/2023Needham & Company LLCReiterated RatingBuy$24.00Low
4/3/2023Needham & Company LLCLower TargetBuy$33.00 ➝ $24.00Low
4/3/2023Piper SandlerLower TargetOverweight$30.00 ➝ $25.00Low
4/3/2023HC WainwrightLower TargetBuy$45.00 ➝ $25.00Low
8/31/2022HC WainwrightLower TargetBuy$70.00 ➝ $45.00Low
8/31/2022Needham & Company LLCLower TargetBuy$41.00 ➝ $33.00Low
8/30/2022Piper SandlerLower TargetOverweight$35.00 ➝ $30.00Low
8/17/2022Needham & Company LLCLower TargetBuy$72.00 ➝ $41.00Low
5/31/2022Needham & Company LLCLower TargetBuy$85.00 ➝ $72.00High
5/31/2022HC WainwrightLower TargetBuy$80.00 ➝ $70.00High
5/27/2022Piper SandlerLower Target$80.00 ➝ $35.00Low
3/30/2022HC WainwrightLower TargetBuy$95.00 ➝ $80.00Medium
3/29/2022Piper SandlerLower Target$90.00 ➝ $80.00High
12/9/2021Siebert Williams ShankInitiated CoverageBuy$96.00Medium
11/1/2021Needham & Company LLCBoost TargetBuy$83.00 ➝ $85.00Medium
9/1/2021HC WainwrightReiterated RatingBuy$75.00 ➝ $95.00Medium
7/13/2021Cantor FitzgeraldBoost TargetOverweight$90.00 ➝ $95.00Medium
6/10/2021Cantor FitzgeraldBoost TargetPositive ➝ Overweight$76.00 ➝ $90.00High
6/2/2021Daiwa Capital MarketsInitiated CoverageBuyHigh
3/30/2021HC WainwrightReiterated RatingBuyMedium
3/15/2021Needham & Company LLCInitiated CoverageBuy$75.00Medium
3/3/2021HC WainwrightBoost TargetBuy$55.00 ➝ $75.00Low
2/25/2021Piper SandlerInitiated CoverageOverweight$75.00High
12/7/2020HC WainwrightInitiated CoverageBuy$55.00High
9/8/2020Cantor FitzgeraldBoost TargetPositive ➝ Overweight$50.00 ➝ $55.00High
9/1/2020Cantor FitzgeraldReiterated RatingOverweightMedium
7/27/2020Cantor FitzgeraldInitiated CoverageOverweight$50.00High
2/13/2020CICC ResearchInitiated CoverageOutperform$18.09Low
2/11/2020Jefferies Financial GroupInitiated CoverageBuy$16.00Low
(Data available from 4/27/2019 forward)

News Sentiment Rating

0.52 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/30/2023
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/30/2023
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/29/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/29/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/28/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/27/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
3/28/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/27/2024

Current Sentiment

  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

I-Mab logo
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
Read More

Today's Range

Now: $1.80
Low: $1.80
High: $1.83

50 Day Range

MA: $1.79
Low: $1.57
High: $1.90

52 Week Range

Now: $1.80
Low: $1.16
High: $3.45

Volume

88,595 shs

Average Volume

215,709 shs

Market Capitalization

$145.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11

Frequently Asked Questions

What sell-side analysts currently cover shares of I-Mab?

The following Wall Street sell-side analysts have issued stock ratings on I-Mab in the last twelve months: Cantor Fitzgerald, HC Wainwright, Needham & Company LLC, and Piper Sandler.
View the latest analyst ratings for IMAB.

What is the current price target for I-Mab?

4 Wall Street analysts have set twelve-month price targets for I-Mab in the last year. Their average twelve-month price target is $12.25, suggesting a possible upside of 580.6%. Cantor Fitzgerald has the highest price target set, predicting IMAB will reach $25.00 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $6.00 for I-Mab in the next year.
View the latest price targets for IMAB.

What is the current consensus analyst rating for I-Mab?

I-Mab currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IMAB will outperform the market and that investors should add to their positions of I-Mab.
View the latest ratings for IMAB.

What other companies compete with I-Mab?

Other companies that are similar to I-Mab include Incannex Healthcare, Biophytis, Regulus Therapeutics, CervoMed and Capricor Therapeutics. Learn More about companies similar to I-Mab.

How do I contact I-Mab's investor relations team?

I-Mab's physical mailing address is SUITE 802 WEST TOWER OMNLVISION 88 SHANGKE ROAD PUDONG DISTRICT, SHANGHAI F4, 201210. The company's listed phone number is 86-21-6057-8000 and its investor relations email address is [email protected]. The official website for I-Mab is www.i-mabbiopharma.com. Learn More about contacing I-Mab investor relations.